Current Edition

gene-editing

Intellia, expanding in gene editing, buys startup Rewrite for $45M

Dive Brief: Intellia Therapeutics, a leading developer of CRISPR-based medicines, on Thursday said it will buy privately held Rewrite Therapeutics for $45 million, as it …

Continue Reading →
Beam

Beam gets green light to begin first clinical test of base editing

Gene editing’s promise is clearest, and perhaps closest, in sickle cell disease, a hereditary condition characterized by deformed, or “sickled,” red blood cells that cause …

Continue Reading →
Biotech

Moderna, teaming with a startup, wades further into gene editing

Before it rose to prominence as a vaccine maker, Moderna’s original ambitions were to use its messenger RNA technology — a way to prompt the …

Continue Reading →
CRISPR

Vertex aligns with another CRISPR gene editing startup

Mammoth’s evolution into a drugmaker appears to be paying off. Three years ago, the company formed with a plan to use CRISPR gene editing to …

Continue Reading →
Biotech

Vertex, looking to broaden its gene editing abilities, asks a young biotech for help

Vertex is best known for its work in cystic fibrosis, having developed four approved medicines that, by the company’s estimates, can treat about 90% of …

Continue Reading →
clinical

Vertex, CRISPR gene-editing therapy hit with clinical hold

U.S. regulators have placed a clinical hold on CRISPR Therapeutics’ lead candidate, spurring a double-digit drop in the Swiss biotech’s stock value by Thursday morning. …

Continue Reading →